Category: Kinase Inhibitor Library

Resistance to kinase inhibitors may also be effected by MLN4924 aberrant activation of redundant signalling pathways to that of the target, an example being MET amplification inresistancetoEGFR kinase inhibitors. As CEM/ AKB16 cells were highly resistant to Aurora B inhibition it appears that sustained Aurora B activity in the presence of ZM447439 may still be driving resistance in these cells rather than activation of an alternative pathway. Previous work from our laboratory on drug resistance mediated by tubulin mutations showed that CEM cells acquire additional point mutations in tubulin at higher levels of resistance. Both CEM/AKB8 and CEM/AKB16 cells expressed the Aurora B G160E mutation described for CEM/ AKB4 cells, however no additional mutations in Aurora B were observed, further demonstrating theimportance of the160 residue in drug binding and high-level resistance. Our study of phosphorylated Histone H3 levels showed that CEM/AKB4 cells maintain resistance to Aurora B inhibition at 16 mM ZM, despite this drug concentration being sufficient to induce apoptosis and cell death. This is consistent with off-target kinase inhibition of ZM447439, where at high drug concentrations the contribution of targeting additional cytotoxic pathways to Aurora B inhibition becomes significant. Therefore the resistant phenotype in CEM/AKB16 cells may potentially be mediated LEE011 through alterations in these other targets of ZM447439. ZM447439 has been shown to potently inhibit Aurora A as well as Aurora B in biochemical assaysand we analysed CEM/AKB16 cells for alterations in Aurora A. We found no changes in gene or protein expression of Aurora A in CEM/AKB16 cells and no mutations in the Aurora A gene. Additionally, CEM/AKB16 cells were as equally sensitive as CEM cells to a selective Aurora A inhibitor MLN8237, suggesting that ZM447439 resistance in these cells is not mediated through an Aurora A dependent pathway. It is possible that alterations in other unknown targets of ZM447439 may be responsible, and ultimately, an understanding of the precise mechanisms underpinning resistance in the more highly resistant CEM/AKB8 and CEM/AKB16 cells will shed further light on the mode of action of this drug. Aurora B inhibitors remain a promising area for targeted anticancer therapy, yet a fuller understanding of drug response and resistance mechanisms will aid their clinical implementation. Our findings have confirmed that resistance to these agents is likely across a variety of malignancies and that point mutations in Aurora B, particularly of the 160 residue, may be highly significant markers of treatment outcome. Moreover, our analysis of highly resistant cells suggests that sustained or high-level drug treatment may give rise to an evolution of multiple mechanisms of resistance in patients. Accordingly, our models provide a basis for designing and testing alternative Aurora B inhibitors, and for screening agents that may be employed in combination therapeutic approaches. The two highly homologous human tankyrase isoforms, TNKS1 and TNKS2, are members of the poly ADP-ribose polymerasefamily of 17 proteins that share a catalytic PARP domain. These PARP proteins cleave NAD+into ADP-ribose and nicotinamide and transfer the ADP-ribose units onto their substrates, resulting in a post-translational modification referred to as PARsylation. Cellular functions of many PARP proteins remain unknown. PARP1 and PARP2, the two best characterized family members, are key players in homologous recombination DNA damage response and have been pursued as cancer targets for over a decade. Structural studies of PARP inhibitor complexes reveal that these compounds are anchored in the nicotinamide pocket in a very similar manner.

Additionally, recent reports revealed that upregulated myc expression sensitizes cells for therapeutics targeting CK1e. In our studies, IC261 induced a transient full G2/M arrest at a cell type dependent concentration. We have also shown that at half of this concentration ) the subG1 population increases. This increase of apoptotic cells cannot be due to G2/ M arrest, because at IC50 the population of 4N cells is not significantly increased. It was shown, that CK1 phosphorylates Bid and thereby prevents cleavage by caspase 8. Therefore an inhibition of CK1 at low concentrations of IC261 could lead to activation of pro-apoptotic protein Bid and thereby to increased apoptosis indicated by increased subG1 population. However, it remains unclear why at higher concentrations of IC261 the cell cycle arrest at G2/M is dominant over the pro-apoptotic effect. In summary this study provides data that extends the knowledge of IC261 induced effects in cells. We demonstrate that the CK1 kinase inhibitor IC261 mediates off-CK1-target effects by depolymerizing MTs in a dose-dependent and reversible manner. Therefore, results of previous studies using IC261 as a CK1 inhibitor should be interpreted carefully. Here, we also present evidence that CK1 is neither localized at the TGN nor at the GA, but co-localizes with the COPI protein b-COP. Opportunistic pathogens secrete multiple virulence factors to modulate interactions with the host, to acquire nutrients from the environment and to facilitate adhesion and colonization to a variety of substrates. Pseudomonas aeruginosa secretes a series of proteases that target host proteins to modulate the immune response and to facilitate colonization in infected tissues. Bacterial adherence and colonization may be facilitated by the degradation of host immune and signaling proteins that would otherwise initiate or potentiate the host response. Alternatively, remodeling the local environment of a bacterium may promote its adherence or growth. While the pathophysiological mechanisms in patients have not been fully elucidated, AP has been shown to cleave bacterial flagellin, host signaling molecules and the epithelial ARRY-142886 sodium channel. Cleavage of flagellin and cytokines would putatively alter the host response to the pathogen, while ENaC cleavage would be predicted to remodel the airway surface hydration state, reduce muco-cilliary clearance, and facilitate bacterial adherence and colonization. The combined effects of blunting the host immune response and altering ion channel activity would putatively contribute to an increase in bacterial load within the airway and the apparent virulence of the pathogen. To evaluate the potential use of the aprI inhibitor as a modulator of AP activity in airway epithelial cells, AP and AP Inh were purified. Tight association and protease inhibition were CUDC-907 HDAC inhibitor measured in vitro and demonstrated that near stoichiometric addition of the inhibitor completely bound the protease and inhibited its activity. This inhibition was blocked with N-terminal fusions to the inhibitor, consistent with the known structures of the proteaseinhibitor complexes. ENaC-mediated sodium transport in a model cell line and primary airway cultures confirmed that AP addition to the apical bathing surface activated ENaC and that near stoichiometric addition of AP Inh blocked the observed ENaC activation. Similarly, ENaC activation was observed in response to apical addition of serralysin from S. marcescens. This activation was blocked by the addition of the purified AP Inh protein. These data show that multiple M10/serralysin family members can activate ENaC and more broadly implicate the M10 protease family as modulators of ENaC activity.

This publication raises questions about the specificity of IC261 and the interpretation of the reported effects. The situation is complicated by the fact that several studies have suggested that CK1d/e could be directly involved in microtubule dynamics. CK1d co-localizes with spindle microtubules and phosphorylates a- and b-tubulin in vitro. Furthermore, direct interactions between CK1d and microtubule associated proteins, such as MAP1A, MAP4 and end binding SCH772984 moa protein 1 have been reported. In the present study, re-investigation of the subcellular localization of CK1d using high resolution confocal microscopy revealed that CK1d is located in the perinuclear region close to the TGN and Golgi apparatus, but does not co-localize with these compartments. Instead, CK1d partly co-localizes with COPI positive membranes and b-COP. Further studies of the IC261mediated effects on microtubules showed that high concentrations of IC261 disrupt interphase microtubules, finally leading to a dispersed phenotype of perinuclear membranes compartments. This effect of IC261 can be blocked by pretreatment of cells with taxol. Low concentrations of IC261 disrupt spindle microtubules leading to mitotic arrest, post-mitotic arrest or DAPT apoptosis. The effect of IC261 on microtubules is reversible. These results are in line with the recent finding that IC261 can act as a microtubule depolymerizing agent. Therefore, the effects on cells induced by IC261 should be interpreted carefully as such effects may be due to either inhibition of CK1 or the depolymerization of microtubules, or a combination of the two. The evolutionary conserved serine/threonine-specific kinase family CK1 is involved in a broad range of intracellular processes and can be regulated by intracellular compartmentalization. We here provide evidence that CK1d is localized at perinuclear membrane compartments and co-localizes with b-COP, a subunit of the coatomer protein complex coating COPI vesicles. Treatment of cells with the CK1-inhibitor IC261 induces changes in CK1d localization as well as changes of other membrane compartments such as the TGN and Golgi apparatus, most likely due to depolymerization of microtubules. The aim of the present study was to unravel the various effects of IC261 described in recent years on CK1d, on microtubule dynamics, and on membrane transport processes. Since it has been reported that CK1d is localized on several intracellular membrane compartments, e.g. TGN or GA, we investigated the subcellular localization of CK1d by fluorescence microscopy at high resolution and found that CK1d neither co-localizes with the TGN nor GA structures, but is in close proximity to both compartments. This finding was confirmed by using multiple antibodies for CK1d and for typical TGN and GA markers in two rat cell lines. Whereas the GA and TGN compartments looked like the well-known stack of cisternae, CK1d-positive structures appeared more vesicular and in close proximity to the TGN and GA. Furthermore CK1d seemed to be closer to the GA markers than the TGN marker. Interestingly, CK1d showed partial co-localization with bCOP positive vesicles. b-COP is a subunit of the coatomer complex coating COPI vesicles, which are responsible for retrograde GA-to-ER or intra-GA membrane transport processes. The hypothesis that CK1d could be involved in GA-ER transport is supported by CK1d co-localizes with another coatomer protein b’-COP, and by the report of CK1d regulating membrane binding of ARF GAP1 – a protein stimulating GTPase activity of ARF1, which is required for the uncoating of COPI vesicles. However, in the latter report IC261 was used at high concentration for experiments in cells. The authors argue that in vitro experiments use a lower ATP concentration, whereas intracellular ATP concentrations in vivo are higher.

Recently, we have shown that 10058-F4 also reduces MYCN/MAX interaction in addition to c-MYC/MAX and that it induces selective apoptosis and cell growth arrest in MYCN-amplified compared to nonMYCN amplified NB cells. Furthermore we demonstrated significantly delayed tumor growth in a NB xenograft and increased survival in a transgenic mouse model of NB. These results are in contrast with a previous report that showed no significant antitumor activity of 10058-F4 in a xenograft model of prostate cancer. The differences might be due to the targeting of MYCN as well as c-MYC by 10058-F4 in NB, as well as to a potential greater reliance of NB cells on MYCN for their survival. Inspired by our earlier findings, we explored whether additional compounds shown to modulate c-MYC function could also bind MYCN and inhibit its function in NB cells. Here, extensive characterization of five compounds has been carried out including monitoring of their binding to MYCN as well as their effects in cellular assays used in our previous study. Our SPR analysis showed binding to both c-MYC and MYCN for all compounds tested except for the non-binder 7RH. The estimated KD values showed a similar affinity of 10058-F4 to both proteins. The approximate affinities we could determine were higher than the originally reported KD-values, which might be due to the fact that in the fluorescence polarization assay the bHLHZip domain is free in solution, while in the SPR-based assay it is immobilized on the chip surface by amine coupling and thus physically constrained. However we were encouraged by the fact that 10058-F4 also bound to MYCN with an approximately equal affinity as to cMYC. 10058-F4 is proposed to bind preferentially to Tyr402 and the hydrophobic region ARRY-142886 between residues 401 and 406 in c-MYC. As shown in Figure 1, MYCN also contains a Tyr at the analogous position as well as a highly homologous hydrophobic region. Taken together, these experiments suggest that the full biological effects of MYC inhibiting compounds are most apparent not only when the binding between MYCN and MAX is inhibited but when the levels of MYCN protein are reduced as well. Residual MYC activity may thus be sufficient to permit continued mitochondrial function, thus preventing the accumulation of neutral lipids. The serine hydrolase a/b-hydrolase domain containing 12 is a membrane-bound enzyme that together with monoacylglycerol lipase and ABHD6 contributes to the metabolism of the endocannabinoid 2-arachidonoylglycerol in vitro. In vivo, ABHD12 serves as a lysophospholipase showing preference towards lysophosphatidylserine in the mammalian nervous system. Even though ABHD12 is still poorly characterized, recently developed ABHD122/2 mice have shed some light to its possible physiological functions. In the study of Blankman et al., ABHD12 deficient mice developed age dependent symptoms that resemble the human neurodegenerative disorder PHARC. Authors suggested that the disrupted LPS metabolism and resulting neuroinflammation may form one of the molecular basis for PHARC. Tissue distribution and subcellular localization of MAGL, ABHD6 and ABHD12 are different, suggesting that these hydrolases could control different pools of 2-AG. An active site of ABHD12 is predicted to face the lumen and/or extracellular space and in the latter position ABHD12 could possibly metabolize extracellular pool of 2-AG. We have recently delineated the monoacylglycerol SJN 2511 substrate preferences of ABHD12 in vitro and found that unlike MAGL, ABHD12 prefers the 1-isomers of unsaturated MAGs over the 2isomers. More detailed pharmacological studies with ABHD12 have been limited due to the lack of selective inhibitor. Preliminary inhibitor profiling has shown that the universal lipase/serine hydrolase inhibitors tetrahydrolipstatin and methyl arachidonyl fluorophosphonate.

Asiatic acid also has an extra hydroxyl group at position 2. However the same substitution and this feature greatly improved the inhibitory activity. In fact, among the 15 commercial compounds tested, maslinic acid was the best hABHD12 inhibitor having an IC50 value of 1.3 mM. The oleanane series further confirmed our findings that dimethyl at position 4 in combination with a carboxyl group at position 17 were important features for hABHD12 inhibition. Finally, we tested four triterpenoids, 2-cyano-3,12dioxo-oleana-1,9-dien-28-oic acid, CDDO methyl ester, celastrol, and the established MAGL inhibitor pristimerin. All four derivatives failed to show any inhibition of hABHD12 and the findings with pristimerin are in agreement with those in the study by King et al. where pristimerin was tested against different endocannabinoid targets. Poor inhibitory PCI-32765 activity of triterpenoids 12�C15 allowed us to conclude that triterpene backbone was crucial for the hABHD12 inhibitor activity. As betulinic acid, ursolic acid and oleanolic acid had only minor differences in their inhibitory activities, neither the size of the ring E nor its substituents have a role in hABHD12 inhibition. In order to establish additional structural features that are critical for hABHD12 inhibition, we chose a series of previously reported derivatives of betulinic acid for further evaluation. Importance of the carboxyl group at position 17 was further verified by testing an aldehyde 16 which only weakly inhibited hABHD12 at 10 mM concentration. When comparing two similar aldehydes, the inhibition was enhanced to moderate level when hydroxyl substituent at position 3 was replaced to carbonyl, i.e. a plain hydrogen bond accepting group. An amide bond as well as an insertion of an ester or ether similarly decreased inhibitor activity. When carboxyl group was replaced with an oximino group, modest inhibitory activity was observed. Inhibitory activity of the oxime 24 was retained by replacing hydroxyl group at position 3 with another oximino group. When carboxyl group at position 17 was retained and an oximino group was added at position 3, decreased inhibitory activity was observed. However, it was interesting that compound 19 was able to fully inhibit the enzyme whereas maximum inhibition of the compound 24 was only 61%. The effect of the modifications on the ring A on hABHD12 inhibitor activity are presented in the Figures 3�C4 and Table S3. As shown in the case of maslinic acid, an additional hydroxyl group at the position 2 ABT-199 resulted in good inhibition. We synthesized the corresponding betulinic acid derivative 32 and observed that the activity of this compound was similar to that of the parent betulinic acid. Additional heterocyclic ring system attached to the ring A generally gave good inhibition. For example, when hydroxyl groups at positions 2 and 3 were protected as an acetonide, modest inhibitory activity was observed. Replacement of a ring A with a lactam ring resulted in modest inhibitory activity, however, the lactam ring also decreased selectivity, as compound 35 also inhibited MAGL. Introduction of a pyridine or a pyrazine ring or an indole ring revealed an important structural feature. The position of a nitrogen atom in the pyridine ring turned out to be important for the inhibitory activity as the compound 41 showed improved activity over the compound 40. Activity was further improved by replacing the pyridine ring with an indole ring or a pyrazole. In fact, compound 33 was the most potent compound of the entire series having an IC50 value of 0.9 mM. As evidenced by the total loss of the inhibitory activity in the case of the indole-fused allobetulin derivative 35, the carboxyl group at position 17 was still needed for inhibitory activity.